High-yield points
- Mechanism:
- high intensity: a thermal lesion with no incision, under MR thermometry;
- low intensity with microbubbles: transient BBB opening .
- Essential tremor (Vim):
- Effect: hand tremor improved about 47% from baseline (8.3 points more than sham), and remained 38–50% better than baseline at 3 years in uncontrolled follow-up.
- Early side effects: gait disturbance (36%) and paresthesias (38%), mostly transient .
- Parkinson disease:
- Subthalamotomy: improves treated-side motor scores (8.1 points over sham).
- Pallidotomy: response 69% vs. 32% with sham (completers) .
- Skull density ratio screens candidates. Skull thickness and volume show consistent associations with outcome and are promising alternatives .
- Children: investigational, with about 22 reported patients. BBB opening for diffuse midline glioma has been done in 3 children, without sedation, as often as every 2 days; one death occurred with two-site treatment, judged unlikely to be FUS-related .
Landmark papers
- Elias et al., N Engl J Med 2016: randomized sham-controlled trial of focused ultrasound thalamotomy for essential tremor (76 patients). Hand tremor scores fell from 18.1 to 9.6 (sham 16.0 to 15.8), a difference of 8.3 points .
Transcranial focused ultrasound converges many ultrasound beams through the intact skull onto a small target.
- High intensity (HIFU): heats the target to create a lesion, with no incision, under MRI guidance and real-time MR thermometry.
- Low intensity: combined with microbubbles, it can open the blood–brain barrier (BBB) temporarily, or modulate neural activity.
- Established and studied uses: in adults, ablation of the thalamus for tremor; pallidal and subthalamic ablation for Parkinson disease have been tested in sham-controlled trials (see caveats on regulatory status).
- In children it is investigational, but it is attractive for deep lesions and drug delivery .
Mechanism and technique
- Thermal ablation:
- The patient lies in an MRI with a hemispherical phased-array transducer coupled to the shaved scalp by a chilled, degassed water bath.
- Low-energy test sonications confirm the target. Energy is then raised until MR thermometry shows an ablative temperature at the focus, with the awake patient tested between sonications (see caveats).
- Patient selection: the skull density ratio (SDR):
- What it is: the approved screening metric for how well a skull transmits ultrasound.
- Its limits: SDR predicts poorly in some patients.
- Alternatives: skull thickness and volume correlate consistently with thermal and clinical outcomes .
- Low-intensity uses:
- BBB opening: intravenous microbubbles oscillate in the ultrasound field and open the BBB, usually transiently, so drugs or antibodies can reach a target region. Early data suggest it is safe, but opening can be prolonged .
- Neuromodulation: low-intensity pulsed sonication is under study (see caveats).
Current indications in adults
- Essential tremor (Vim thalamotomy):
- Randomized sham-controlled trial (76 patients) :
- Hand tremor: scores fell from 18.1 to 9.6 at 3 months (sham 16.0 to 15.8), a between-group difference of 8.3 points.
- Durability: benefit was maintained at 12 months.
- Adverse effects:
- gait disturbance in 36% (persisting at 12 months in 9%);
- paresthesias or numbness in 38% (persisting in 14%).
- Three-year follow-up:
- Hand tremor: improved 38–50%.
- Disability: improved 43–56%.
- Safety: no progressive or delayed complications; some mild waning since 6 months .
- ASSFN position statement (2026) :
- Effect: about 47% short-term improvement from baseline in hand tremor in the treated arm of the sham-controlled RCT (8.3 points better than sham ), with durable benefit in uncontrolled follow-up .
- Bilateral treatment: staged second-side treatment works as well as the first.
- Common early effects: gait disturbance and paresthesias, which tend to fade. Others: dysarthria, ataxia, taste disturbance, motor deficits and speech difficulty.
- Parkinson disease:
- Tremor (thalamotomy): effective short term. Long-term durability is uncertain .
- Subthalamotomy (RCT, 40 patients with asymmetric PD) :
- Off-medication motor score on the treated side: 19.9 to 9.9 at 4 months (sham 18.7 to 17.1), a between-group difference of 8.1 points.
- Adverse events:
- dyskinesia;
- weakness;
- speech disturbance (15 patients, persisting in 3 at 4 months);
- gait disturbance (13 patients, persisting in 2 at 4 months);
- some deficits still present at 12 months in 6 patients.
- Pallidotomy (GPi) (RCT, 94 patients) :
- Response at 3 months (at least a 3-point improvement on the MDS-UPDRS III or the dyskinesia scale): 69% (45/65) vs. 32% (7/22) with sham.
- Durability: 30 of 39 responders were still responding at 12 months.
- Adverse events: dysarthria, gait disturbance, loss of taste, visual disturbance and facial weakness.
- BBB opening (investigational): in Alzheimer disease, BBB opening appears safe and is being studied to increase antibody delivery .
Complications (adults)
- Thermal lesions cause target-specific deficits that often improve :
- Vim thalamotomy: gait or balance problems and sensory symptoms.
- Subthalamotomy: dyskinesia, weakness and speech changes.
- Pallidotomy: dysarthria and visual or taste disturbance.
- Procedure-related (see caveats):
- scalp heating or burns;
- pain and headache during sonication;
- nausea and vertigo;
- frame-pin discomfort.
- What it avoids: hemorrhage and infection are unusual compared with open or electrode-based surgery, because there is no incision.
- Its limitation: a lesion is permanent and not adjustable, unlike DBS (see caveats).
Future uses in children
- Pediatric scoping review (20 studies) :
- Clinical reports: only 22 children:
- 10 had thermal ablation of brain tumors or lesions;
- 11 had sonodynamic therapy of brainstem tumors without adverse effects;
- 1 had BBB opening before doxorubicin.
- Preclinical work: low-intensity FUS for drug delivery to diffuse midline glioma and medulloblastoma.
- First-in-pediatric BBB opening trial (relapsed diffuse midline glioma, 3 children, oral panobinostat) :
- Device: neuronavigation-guided (not MRI-helmet) FUS.
- Feasibility: it opened the BBB as often as every 2 days, without sedation.
- Safety: 22 single-site procedures had no serious adverse events. With two-site treatment, opening was prolonged, and one grade 5 event (a death) occurred that was judged unlikely to be related to FUS.
- Why children are different (see caveats):
- thin and evolving skulls (open sutures and fontanelles change acoustic transmission);
- the need for sedation or anesthesia to stay still in the MRI helmet;
- target size;
- the long-term effects of thermal lesions in the developing brain.
- Candidate pediatric targets under discussion (see caveats):
- deep lesions now treated by LITT (hypothalamic hamartoma, small epileptogenic lesions);
- drug delivery for diffuse midline glioma and other brain tumors;
- sonodynamic therapy.
Related topics
- LITT in Epilepsy Surgery: the established minimally invasive ablation.
- Hypothalamic Hamartoma: a deep lesion treated by ablation.
- DBS for Dystonia: the neuromodulation alternative.
- Epilepsy Surgery Overview: surgical context.
References
- Hamani C, Elias WJ, Baltuch GH, et al. Magnetic resonance-guided focused ultrasound for the management of tremor: update on the position statement of the American Society for Stereotactic and Functional Neurosurgery. J Neurosurg 2026;145(1):4–12. doi:10.3171/2025.11.JNS251828. PMID 41894813. verified
- Elias WJ, Lipsman N, Ondo WG, et al. A randomized trial of focused ultrasound thalamotomy for essential tremor. N Engl J Med 2016;375(8):730–739. doi:10.1056/NEJMoa1600159. PMID 27557301. verified
- Halpern CH, Santini V, Lipsman N, et al. Three-year follow-up of prospective trial of focused ultrasound thalamotomy for essential tremor. Neurology 2019;93(24):e2284–e2293. doi:10.1212/WNL.0000000000008561. PMID 31748250. verified
- Martínez-Fernández R, Máñez-Miró JU, Rodríguez-Rojas R, et al. Randomized trial of focused ultrasound subthalamotomy for Parkinson's disease. N Engl J Med 2020;383(26):2501–2513. doi:10.1056/NEJMoa2016311. PMID 33369354. verified
- Krishna V, Fishman PS, Eisenberg HM, et al. Trial of globus pallidus focused ultrasound ablation in Parkinson's disease. N Engl J Med 2023;388(8):683–693. doi:10.1056/NEJMoa2202721. PMID 36812432. verified
- Arora V, Sadeghi A, Lim B, et al. Beyond skull density ratio for magnetic resonance-guided focused ultrasound: a literature review of the alternatives. Neurosurgery 2026 (online ahead of print). doi:10.1227/neu.0000000000004118. PMID 42283469. verified
- Patwardhan A, Wilkinson T, Meng Y, et al. Safety, efficacy and clinical applications of focused ultrasound-mediated blood brain barrier opening in Alzheimer's disease: a systematic review. J Prev Alzheimers Dis 2024;11(4):975–982. doi:10.14283/jpad.2024.85. PMID 39044508. verified
- Hersh AM, Jillala R, Kramer P, et al. Focused ultrasound in pediatric neurosurgery: a scoping review of opportunities and challenges. Childs Nerv Syst 2025;41(1):210. doi:10.1007/s00381-025-06863-9. PMID 40500553. verified
- Wu CC, Szalontay L, Pouliopoulos AN, et al. Blood-brain barrier opening with neuronavigation-guided focused ultrasound in pediatric patients with diffuse midline glioma. Sci Transl Med 2025;17(824):eadq6645. doi:10.1126/scitranslmed.adq6645. PMID 41223245. verified
Verification (2026-11-17):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.
- Reference 6 is online-first.
Caveats:
- The following are standard descriptions, not drawn from the cited abstracts:
- the procedural workflow (helmet, water bath, test sonications, awake testing);
- neuromodulation;
- procedure-related side effects;
- the rarity of hemorrhage and infection;
- irreversibility compared with DBS;
- pediatric-specific challenges and candidate targets.
- All indication and complication data are from adults.
- Regulatory approval status differs by country and changes over time. Thalamotomy for essential tremor is the most widely approved indication; check current approvals for Parkinson disease targets.
- Pediatric experience is limited to small case series and one first-in-pediatric feasibility trial.
- The figure is an original schematic.